Investigation Launched by Pomerantz LLP Regarding Nyxoah S.A. (NYXH)
New York, NY – March 27, 2025
Pomerantz LLP, a leading national securities law firm, announces that a class action lawsuit has been filed against Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH) on behalf of investors. The action was filed in the United States District Court for the Southern District of New York and alleges that Nyxoah and certain of its officers and directors have violated the Securities Exchange Act of 1934.
Background
Nyxoah is a Belgian company that specializes in the development and commercialization of innovative solutions for the treatment of sleep-disordered breathing, including obstructive sleep apnea (OSA) and central sleep apnea (CSA).
The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that:
- Nyxoah’s sales and marketing efforts were not generating the expected revenue growth;
- The Company was experiencing production issues with its flagship product, the Genio system;
- The Company was facing increased competition in the sleep apnea market;
- The Company’s financial statements were not accurate;
Impact on Individual Investors
The investigation may have significant implications for individual investors. If the allegations are true, investors may be able to recover their losses through the class action lawsuit. It is important for investors to remain vigilant and closely monitor any developments in the case. Investors who purchased or otherwise acquired Nyxoah securities during the Class Period should contact Pomerantz LLP for a consultation.
Impact on the World
The impact of this investigation on the world at large extends beyond the financial markets. The allegations against Nyxoah raise concerns about the accuracy and reliability of information provided by publicly traded companies, particularly in the healthcare sector. This can lead to a loss of confidence in the market and a decrease in investment activity. It also highlights the importance of robust regulatory frameworks and effective enforcement mechanisms to protect investors and maintain market integrity.
Conclusion
The investigation into Nyxoah S.A. by Pomerantz LLP is a reminder of the importance of transparency and accuracy in corporate reporting. It also underscores the potential consequences of misleading statements and non-compliance with securities laws. As the case progresses, it will be important to monitor developments closely and consider the implications for investors and the broader market.
Pomerantz LLP is committed to advocating for investors and ensuring that they are treated fairly. If you have any questions or concerns regarding this investigation or your investment in Nyxoah, please contact the firm.
